Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Schatz S, Falk M, Jóri B, Ramdani HO, Schmidt S, Willing EM, Menon R, Groen HJM, Diehl L, Kröger M, Wesseler C, Griesinger F, Hoffknecht P, Tiemann M, Heukamp LC. Schatz S, et al. Among authors: griesinger f. Cancers (Basel). 2020 Jun 24;12(6):1685. doi: 10.3390/cancers12061685. Cancers (Basel). 2020. PMID: 32599951 Free PMC article.
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.
Roeper J, Falk M, Chalaris-Rißmann A, Lueers AC, Ramdani H, Wedeken K, Stropiep U, Diehl L, Tiemann M, Heukamp LC, Otto-Sobotka F, Griesinger F. Roeper J, et al. Among authors: griesinger f. Oncotarget. 2020 Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430. eCollection 2020 Jan 21. Oncotarget. 2020. PMID: 32076486 Free PMC article.
Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
Ramdani HO, Falk M, Heukamp LC, Schatz S, Tiemann M, Wesseler C, Diehl L, Schuuring E, Groen HJM, Griesinger F. Ramdani HO, et al. Among authors: griesinger f. Pathol Res Pract. 2021 Nov;227:153651. doi: 10.1016/j.prp.2021.153651. Epub 2021 Oct 12. Pathol Res Pract. 2021. PMID: 34673351 Free article.
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Among authors: griesinger f. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981
216 results